Literature DB >> 18174712

ACROSTUDY: an overview.

Peter J Trainer1.   

Abstract

Mesh:

Substances:

Year:  2007        PMID: 18174712     DOI: 10.1159/000110480

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


× No keyword cloud information.
  4 in total

1.  Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY.

Authors:  Pamela U Freda; Murray B Gordon; Nicky Kelepouris; Peter Jonsson; Maria Koltowska-Haggstrom; A J van der Lely
Journal:  Endocr Pract       Date:  2015-03       Impact factor: 3.443

2.  Safety of long-term treatment with Pegvisomant: analysis of Spanish patients included in global ACROSTUDY.

Authors:  I Bernabeu; A Pico; E Venegas; J Aller; C Alvarez-Escolá; J A García-Arnés; M Marazuela; P Jonsson; N Mir; M García Vargas
Journal:  Pituitary       Date:  2016-04       Impact factor: 4.107

3.  Are there country-specific differences in the use of pegvisomant for acromegaly in clinical practice? An analysis from ACROSTUDY.

Authors:  S Grottoli; A Bianchi; F Bogazzi; C Bona; M O Carlsson; A Colao; F Dassie; A Giampietro; R Gomez; S Granato; P Maffei; R Pivonello; N Prencipe; M Ragonese; C Urbani; S Cannavò
Journal:  J Endocrinol Invest       Date:  2022-03-31       Impact factor: 5.467

Review 4.  Diabetes Secondary to Acromegaly: Physiopathology, Clinical Features and Effects of Treatment.

Authors:  Francesco Ferraù; Adriana Albani; Alessandro Ciresi; Carla Giordano; Salvatore Cannavò
Journal:  Front Endocrinol (Lausanne)       Date:  2018-07-06       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.